Fig. 1From: Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rateKaplanāMeier curves of patients with pathological stage N2 rectal cancer treated with primary adjuvant concurrent chemoradiotherapy (A-CRT) or primary adjuvant chemotherapy (A-CT). a The 3-year distant metastasis-free survival rates are 67.5% in the A-CRT group and 86.6% in the A-CT group (pā=ā0.074). b The 3-year locoregional recurrence-free survival rates are 93.7% in the A-CRT group and 97.4% in the A-CT group (pā=ā0.629). c The 3-year disease-free survival rates are 66.7% in the A-CRT group and 83.9% in the A-CT group (pā=ā0.153). d The overall survival rates are 81.8% in the A-CRT group and 90.8% in the A-CT group (pā=ā0.378)Back to article page